Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN104 Maintenance Post-HSCT in Acute Leukemia
NCT07101497Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zefamenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia of ambiguous lineage (ALAL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Relapse-Free Survival at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
zefamenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT07101497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101497.